The company exhibits a lack of scalable revenue, reporting no top-line growth in eight of the last ten quarters while maintaining a consistent operating loss, most recently at $3.3 million in 2025Q1.
| Sales/Revenue | 1.07M | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -18.72% | - | - | - | - | - | - |
| Cost of Goods Sold | 270K | 0 | 915K | 939K | 340K | 173K | 173K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 264K | 0 | -915K | -939K | -340K | -173K | -173K |
| Gross Margin % | 24.72% | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | 2.56% | -176.18% | -96.54% | 0% | - |
| Operating Expenses | 27.32M | 31.46M | 41.69M | 71.11M | 62.66M | 10.71M | 45K |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 15.37M | 15.98M | 13.64M | 18.95M | 22.57M | 3.6M | 45K |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 11.95M | 15.49M | 28.06M | 52.15M | 40.08M | 7.12M | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -27.32M | -31.46M | -42.61M | -68.72M | -62.66M | -10.71M | -45K |
| Operating Margin % | -2557.96% | - | - | - | - | - | - |
| Operating Income Growth % | - | 26.16% | 38% | -9.68% | -484.8% | -23708.89% | - |
| EBITDA | -26.49M | -31.46M | -41.69M | -67.78M | -62.32M | -15.85M | 9K |
| EBITDA Margin % | -2480.62% | - | - | - | - | - | - |
| EBITDA Growth % | 21.99% | 24.54% | 38.49% | -8.77% | -293.16% | -176211.11% | - |
| D&A (Non-Cash Add-back) | 826K | 0 | 915K | 939K | 340K | 0 | 54K |
| EBIT | -27.32M | 0 | -40.16M | -62.98M | -39.31M | -15.85M | -45K |
| Net Interest Income | 373K | 472K | 1.25M | 664K | 0 | 46.27K | 54.27K |
| Interest Income | 373K | 472K | 1.25M | 664K | 0 | 54.27K | 54.27K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 8K | 0 |
| Other Income/Expense | 4.67M | 1.39M | 2.45M | 5.74M | 23.35M | -5.91M | 0 |
| Pretax Income | -22.64M | -30.07M | -40.16M | -62.98M | -39.31M | -16.62M | -45K |
| Pretax Margin % | -2120.32% | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -22.64M | -30.07M | -40.16M | -65.37M | -39.31M | -16.62M | -54K |
| Net Margin % | -2120.32% | - | - | - | - | - | - |
| Net Income Growth % | 40.79% | 25.11% | 38.57% | -66.3% | -136.5% | -30677.78% | - |
| Net Income (Continuing) | -22.64M | -30.07M | -40.16M | -62.98M | -39.31M | -16.62M | -45K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.33 | -5.75 | -6.84 | -10.86 | -8.30 | -11.67 | -0.03 |
| EPS Growth % | 123.29% | 15.94% | 37.02% | -30.84% | 28.88% | -37065.61% | - |
| EPS (Basic) | - | -5.75 | -6.84 | -10.86 | -8.30 | -11.67 | -0.03 |
| Diluted Shares Outstanding | 5.23M | 5.23M | 5.87M | 5.8M | 4.74M | 1.42M | 1.43M |
| Basic Shares Outstanding | 5.23M | 5.23M | 5.87M | 5.8M | 4.74M | 1.42M | 1.43M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Imminent liquidity depletion risk
As indicated by the company's financial disclosures, Vincerx remains a pre-revenue entity with no consistent product sales, as evidenced by the lack of revenue in eight of the last ten quarters, highlighting a total dependence on future clinical milestones to generate any meaningful top-line growth.
The intermittent revenue spikes observed in 2023Q4 and 2024Q4 appear to be non-recurring in nature, likely tied to one-off licensing or collaboration events rather than commercial traction. This lack of a sustainable revenue stream suggests that the company's growth trajectory is entirely binary and contingent upon the successful clinical validation of its SMDC platform.
Based on reported income statements, Vincerx has consistently allocated the majority of its capital to R&D, with quarterly expenditures peaking at $11.4 million in 2022Q4, reflecting a high-burn model that prioritizes clinical development over the maintenance of a sustainable, long-term operational cost structure.
While R&D spending has moderated from its 2022 highs, the current level of expenditure remains disproportionate to the company's limited cash reserves. The persistent reliance on high-cost clinical trial execution suggests that management may be struggling to balance the necessity of scientific advancement with the harsh reality of a constrained capital environment.
According to the provided income statement data, Vincerx exhibits no operating leverage, as the company continues to report significant operating losses each quarter, with the most recent 2025Q1 operating loss of $3.3 million underscoring the lack of a scalable business model in its current clinical-stage phase.
The absence of gross profit to cover even a fraction of SG&A and R&D expenses implies that the company is currently unable to achieve any form of operational efficiency. Investors should monitor whether management can successfully pivot to a leaner operating model, as the current structure appears to be entirely dependent on external financing.
As reported in financial filings, Vincerx has utilized stock-based compensation as a recurring expense, with $435,000 recorded in 2025Q1, which suggests a strategic effort to preserve cash by substituting equity for salary, though this practice introduces significant dilution risks for existing shareholders over the long term.
The reliance on equity-based incentives appears to be a defensive mechanism to retain specialized talent in the absence of sufficient cash flow. This approach warrants further investigation, as it may indicate that the company's true cost of operations is higher than the cash-based figures suggest, potentially understating the severity of the burn rate.
Based on the reported cash and equivalents of $4.9 million, the company faces a critical liquidity inflection point, as the current burn rate suggests that Vincerx may lack the necessary capital to sustain its clinical programs without immediate and potentially highly dilutive external financing.
The market's current valuation appears to reflect a distressed asset scenario, where the primary risk is not just clinical failure, but the inability to reach the next data readout due to insolvency. Any further delay in securing capital could force management to abandon key pipeline assets, significantly impairing the long-term value proposition of the SMDC platform.
Quick answers to the most common questions about buying VINC stock.
For fiscal year 2024, Vincerx Pharma, Inc. (VINC) reported total revenue of $0.0M.
Vincerx Pharma, Inc. (VINC) reported a net loss of $30.1M for the fiscal year ending 2024.